Tositumomab and iodine I 131 tositumomab
|Generic name||Tositumomab and iodine I 131 tositumomab|
|Brand name(s), other common name(s)||Bexxar®|
|Drug type||Monoclonal antibody, radioimmunotherapy|
|How the drug is given||Intravenously (IV)|
GSK plans to discontinue the manufacture and sale of the BEXXAR therapeutic regimen (tositumomab and iodine I 131 tositumomab). The last day to schedule dosing for BEXXAR will be February 11, 2014 with final patient-availability on February 20, 2014.
The tositumomab and iodine I 131 tositumomab therapeutic regimen is FDA approved to treat patients with CD20-positive, low-grade, follicular non-Hodgkin lymphoma and patients with transformed (faster-growing) non-Hodgkin lymphoma that has not improved or that had improved after treatment with other medications but later returned. It is indicated to be given to patients only once. The safety of multiple courses of the Bexxar® therapeutic regimen, or combination of this regimen with other forms of irradiation or chemotherapy, has not been evaluated.
Side effects needing medical attention:Weakness; infection; bleeding; fever; chills; nausea; cough; diarrhea; rash; swelling at the site of the injection; abdominal pain; dizziness.